Alimentary Pharmacology & Therapeutics, Год журнала: 2022, Номер 56(1), С. 164 - 165
Опубликована: Июнь 10, 2022
LINKED CONTENT This article is linked to Bhurwal et al papers. To view these articles, visit https://doi.org/10.1111/apt.16913 and https://doi.org/10.1111/apt.16935
Язык: Английский
JAMA Network Open, Год журнала: 2022, Номер 5(10), С. e2240037 - e2240037
Опубликована: Окт. 20, 2022
Importance With a large proportion of the US adult population vaccinated against SARS-CoV-2, it is important to identify who remains at risk severe infection despite vaccination. Objective To characterize factors for COVID-19 disease in population. Design, Setting, and Participants This nationwide, retrospective cohort study included veterans received SARS-CoV-2 vaccination series later developed laboratory-confirmed were treated Department Veterans Affairs (VA) hospitals. Data collected from December 15, 2020, through February 28, 2022. Exposures Demographic characteristics, comorbidities, immunocompromised status, vaccination-related variables. Main Outcomes Measures Development vs nonsevere infection. Severe was defined as hospitalization within 14 days positive diagnostic test either blood oxygen level less than 94%, receipt supplemental or dexamethasone, mechanical ventilation, death 28 days. Association between exposures estimated using logistic regression models. Results Among 110 760 patients with infections following (97 614 [88.1%] men, mean [SD] age vaccination, 60.8 [15.3] years; 26 953 [24.3%] Black, 11 259 [10.2%] Hispanic, 71 665 [64.7%] White), 10 612 (9.6%) had COVID-19. The strongest association after age, which increased among aged 50 years older an adjusted odds ratio (aOR) 1.42 (CI, 1.40-1.44) per 5-year increase such that 80 aOR 16.58 13.49-20.37) relative 45 years. Immunocompromising conditions, including different classes immunosuppressive medications (eg, leukocyte inhibitor: aOR, 2.80; 95% CI, 2.39-3.28) cytotoxic chemotherapy (aOR, 2.71; 2.27-3.24) prior breakthrough infection, leukemias lymphomas 1.87; 1.61-2.17) chronic conditions associated end-organ disease, heart failure 1.74; 1.61-1.88), dementia 2.01; 1.83-2.20), kidney 1.59; 1.49-1.69), also risk. Receipt additional (ie, booster) dose vaccine reduced 0.50; 0.44-0.57). Conclusions Relevance In this predominantly male Veterans, we identified Findings could be used inform outreach efforts booster vaccinations clinical decision-making about most likely benefit preexposure prophylaxis antiviral therapy.
Язык: Английский
Процитировано
46
Annals of Medicine, Год журнала: 2025, Номер 57(1)
Опубликована: Март 26, 2025
This study aimed to identify the optimal strategy for patients with autoimmune diseases by comparing immunoreaction and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines between healthy individuals patients. The PubMed, Embase, Cochrane Library were searched eligible studies on SARS-CoV-2 in published until October 07, 2022. quality each included was evaluated independent reviewers using National Institutes Health assessment tool, STATA 15.0 software used all statistical analyses. A total 84 publications analyzed this meta-analysis, favoring controls regarding serological response (risk ratio, RR=0.88, 95% CI (confidence interval): 0.86-0.91), antibody (RR=0.90, 95%CI: 0.87-0.94), incidence seropositive immunoglobulin G (IgG) (RR=0.74, 0.69-0.80) than post-vaccination. Patients developed lower IgG (standard mean difference, SMD=-0.64 -0.84 -0.43) titer level (SMD=-1.39, -2.30 -0.49) AU/ml. Stratified analyses conducted further according various potential factors full-text studies. who are immunocompromised received more demonstrated poorer humoral responses after vaccination individuals. Despite lack observable favor diseases, trend is close that populations. should be provided a better schedule, considering vaccine subtypes, dose(s), variants concern, immunoassays.
Язык: Английский
Процитировано
1
Vaccines, Год журнала: 2022, Номер 10(5), С. 800 - 800
Опубликована: Май 18, 2022
Vaccination is crucial for avoiding infection-associated morbidity and mortality among immunocompromised patients. However, patients respond less well to vaccinations compared healthy people, little known about the relative efficacy of various vaccines different states. A total 54 systematic reviews (22 COVID-19; 32 non-COVID-19) published within last 5 years in Pubmed® were reviewed. They demonstrated similar patterns three seroconversion response categories: good (about >60% when controls), intermediate (~40–60%), poor <40%). Good vaccine responses would be expected with chronic kidney disease, human immunodeficiency virus infection (normal CD4 counts), immune-mediated inflammatory diseases, post-splenectomy states, solid tumors. Intermediate anti-cytotoxic T-lymphocyte antigen-4 therapy, hematologic cancer, (low counts). Poor B-cell-depleting agents (e.g., anti-CD20 therapy), hematopoietic stem-cell transplant, organ liver cirrhosis. For all categories, vaccination should timed are least immunosuppressed. high-dose vaccine, revaccination immunosuppressed, checking seroconversion, additional booster doses, long-acting monoclonal antibodies may considered, supplemented by shielding measures.
Язык: Английский
Процитировано
35
Alimentary Pharmacology & Therapeutics, Год журнала: 2022, Номер 55(10), С. 1244 - 1264
Опубликована: Март 30, 2022
Abstract Introduction There are concerns regarding the effectiveness and safety of SARS‐CoV‐2 vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review meta‐analysis comprehensively summarises available literature IBD. Methods Three independent reviewers performed a comprehensive all original articles describing response vaccines patients with Primary outcomes were (1) pooled seroconversion rate vaccination IBD (2) comparison breakthrough COVID‐19 infection control cohort (3) adverse event vaccine. All evaluated for one two doses Meta‐regression was performed. Probability publication bias assessed using funnel plots Egger’s test. Results Twenty‐one studies yielded 73.7% 96.8% after respectively. Sub‐group analysis revealed non‐statistically significant differences between different immunosuppressive regimens seroconversion. that type study location independently influenced rates. no statistically difference as compared to vaccination. Conclusion In summary, suggest is safe effective
Язык: Английский
Процитировано
23
Journal of Autoimmunity, Год журнала: 2024, Номер 144, С. 103175 - 103175
Опубликована: Фев. 21, 2024
SARS-CoV-2-specific CD8
Язык: Английский
Процитировано
4
The American Journal of Gastroenterology, Год журнала: 2023, Номер 118(8), С. 1388 - 1394
Опубликована: Янв. 30, 2023
INTRODUCTION: To investigate the association between vaccination against coronavirus disease 2019 (COVID-19) and inflammatory bowel (IBD) flare. METHODS: Patients with IBD vaccinated COVID-19 who consulted for flare December 1, 2020, 31, 2021, were ascertained from Clinical Practice Research Datalink. flares identified using consultation corticosteroid prescription records. Vaccinations product codes dates. The study period was partitioned into vaccine-exposed (vaccination date 21 days immediately after), prevaccination (7 before vaccination), remaining vaccine-unexposed periods. Participants contributed data multiple vaccinations flares. Season-adjusted incidence rate ratios (aIRR) 95% confidence intervals (CI) calculated self-controlled case series analysis. RESULTS: Data 1911 cases included; 52% of them female, their mean age 49 years. Approximately 63% participants had ulcerative colitis (UC). not associated increased in when all considered (aIRR [95% CI] 0.89 [0.77–1.02], 0.79 [0.66–0.95], 1.00 [0.79–1.27] overall, UC, Crohn's disease, respectively). Analyses stratified to include only first, second, or third found no significant 0.87 [0.71–1.06], 0.93 [0.75–1.15], 0.86 [0.63–1.17], Similarly, stratification by vectored DNA messenger RNA vaccine did reveal an risk any these subgroups. DISCUSSION: Vaccination regardless prior infection whether vaccines used.
Язык: Английский
Процитировано
7
World Journal of Gastroenterology, Год журнала: 2023, Номер 29(26), С. 4099 - 4119
Опубликована: Июль 6, 2023
Coronavirus disease 2019 (COVID-19) has several extrapulmonary symptoms. Gastrointestinal (GI) symptoms are among the most frequent clinical manifestations of COVID-19, with severe consequences reported in elderly patients. Furthermore, impact COVID-19 on patients pre-existing digestive diseases still needs to be fully elucidated, particularly older population. This review aimed investigate GI tract, liver, and pancreas individuals without previous diseases, a particular focus elderly, highlighting distinctive characteristics observed this Finally, effectiveness adverse events anti-COVID-19 vaccination disorders peculiarities found discussed.
Язык: Английский
Процитировано
7
Acta Dermato Venereologica, Год журнала: 2024, Номер 104, С. adv40009 - adv40009
Опубликована: Май 2, 2024
Immunocompromised individuals, primarily attributable to using immunosuppressants, face heightened COVID-19 risks. Despite the proven efficacy of vaccines, their impact on patients with immune-mediated dermatological diseases remains unclear. This study aims thoroughly examine vaccine immunogenicity, effectiveness, and safety in disease patients. Clinical studies adults that compared vaccinated healthy controls or unvaccinated terms infection, adverse events, exacerbation were searched via electronic databases. Seventeen (1,348,690 participants) included. Seroconversion rates between not different. However, among individuals aged ≤55 years, had lower mean anti-SARS-CoV-2 IgG levels. Immunosuppressed also titres less likely achieve T-cell response. In safety, risk events was higher atopic dermatitis patients, but those psoriasis a reduced risk. Additionally, immunosuppressed fewer events. Vaccinated infection than controls; however, may be induced. conclusion, showed response our meta-analysis, yet vaccination remained effective against well tolerated.
Язык: Английский
Процитировано
2
Alimentary Pharmacology & Therapeutics, Год журнала: 2023, Номер 58(7), С. 678 - 691
Опубликована: Авг. 12, 2023
Vaccine-elicited immune responses are impaired in patients with inflammatory bowel disease (IBD) treated anti-TNF biologics.To assess vaccination efficacy against the novel omicron sublineages BQ.1.1 and XBB.1.5 immunosuppressed IBD.This prospective multicentre case-control study included 98 biologic-treated IBD 48 healthy controls. Anti-spike IgG concentrations surrogate neutralisation SARS-CoV-2 wild-type, BA.1, BA.5, BQ.1.1, were measured at two different time points (2-16 weeks 22-40 weeks) following third dose vaccination. Surrogate was based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Primary outcome tested sublineages. Secondary outcomes proportions participants insufficient neutralisation, impact breakthrough infection, correlation anti-spike concentration.Surrogate all reduced who biologics compared to non-anti-TNF controls (each p ≤ 0.001) visit 1. Anti-TNF therapy (odds ratio 0.29 [95% CI 0.19-0.46]) since (0.85 [0.72-1.00]) associated low, mRNA-1273 (1.86 [1.12-3.08]) high wild-type a β-regression model. Accordingly, higher had 1 0.015). decreased over but increased by infection. correlated neutralisation.Patients show may benefit from prioritisation for future variant-adapted vaccines.
Язык: Английский
Процитировано
6
Vaccines, Год журнала: 2022, Номер 10(8), С. 1265 - 1265
Опубликована: Авг. 6, 2022
The vaccination of immunocompromised children against coronavirus disease 2019 is an important public health issue. We evaluated the serological response, safety, and efficacy BNT162b2 vaccine in with without inflammatory bowel (IBD). A prospective, multicenter, case-control study was conducted a pediatric population, including patients IBD, aged 12-18 years. Clinical characteristics, safety profile, serum samples for surrogate virus-neutralizing antibody testing pre- post-BNT162b2 were assessed. breakthrough infection rate during Omicron outbreak calculated to evaluate efficacy. Fifteen controls twenty-three IBD enrolled. After two doses, median level percentage inhibition highly increased, significant differences between groups (control 96.9 96.3). However, it significantly reduced receiving combination therapy (anti-tumor necrosis factor-α + immunomodulators) relative those other therapies controls. Serious adverse events not observed. 42.1%, statistical groups. Immunization comparable that healthy adolescents terms immunogenicity safety. Nevertheless, preventing caused by variant population insufficient.
Язык: Английский
Процитировано
8